Stemline Therapeutics (NASDAQ:STML) Downgraded by BidaskClub

Stemline Therapeutics (NASDAQ:STML) was downgraded by research analysts at BidaskClub from a “hold” rating to a “sell” rating in a note issued to investors on Friday, January 19th.

Several other research firms have also recently weighed in on STML. Cowen restated a “buy” rating on shares of Stemline Therapeutics in a report on Tuesday, October 31st. HC Wainwright reaffirmed a “buy” rating and issued a $38.00 price objective on shares of Stemline Therapeutics in a research note on Friday, November 10th. ValuEngine raised Stemline Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, December 31st. Finally, Zacks Investment Research raised Stemline Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, January 5th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company. Stemline Therapeutics has an average rating of “Buy” and a consensus price target of $33.75.

Stemline Therapeutics (NASDAQ STML) traded up $0.30 during trading hours on Friday, hitting $15.85. The company had a trading volume of 169,438 shares, compared to its average volume of 338,369. Stemline Therapeutics has a 12-month low of $6.35 and a 12-month high of $17.40. The stock has a market capitalization of $463.55, a PE ratio of -6.17 and a beta of -0.02.

In related news, COO Kenneth Hoberman sold 11,943 shares of the business’s stock in a transaction on Friday, December 15th. The stock was sold at an average price of $14.18, for a total transaction of $169,351.74. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider David Gionco sold 4,250 shares of the business’s stock in a transaction on Wednesday, January 17th. The stock was sold at an average price of $13.43, for a total value of $57,077.50. The disclosure for this sale can be found here. Insiders sold a total of 42,216 shares of company stock worth $591,925 over the last quarter. Company insiders own 15.70% of the company’s stock.

A number of hedge funds have recently made changes to their positions in the stock. C WorldWide Group Holding A S purchased a new stake in Stemline Therapeutics during the 3rd quarter valued at about $1,776,000. Northern Trust Corp grew its stake in Stemline Therapeutics by 18.0% during the 2nd quarter. Northern Trust Corp now owns 274,824 shares of the biopharmaceutical company’s stock valued at $2,529,000 after purchasing an additional 41,898 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in Stemline Therapeutics by 74.9% during the 2nd quarter. Dimensional Fund Advisors LP now owns 120,477 shares of the biopharmaceutical company’s stock valued at $1,108,000 after purchasing an additional 51,578 shares during the last quarter. Lyon Street Capital LLC grew its stake in Stemline Therapeutics by 331.1% during the 3rd quarter. Lyon Street Capital LLC now owns 541,462 shares of the biopharmaceutical company’s stock valued at $6,010,000 after purchasing an additional 415,867 shares during the last quarter. Finally, Cowen Inc. purchased a new stake in Stemline Therapeutics during the 3rd quarter valued at about $420,000. Hedge funds and other institutional investors own 42.85% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Stemline Therapeutics (NASDAQ:STML) Downgraded by BidaskClub” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The original version of this report can be accessed at https://www.dispatchtribunal.com/2018/02/14/stemline-therapeutics-stml-stock-rating-lowered-by-bidaskclub.html.

About Stemline Therapeutics

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

Analyst Recommendations for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply